CLAIMS

1. A lactic acid bacterium-containing composition comprising

a lactic acid bacterium having a human papillomavirus (HPV) E7 protein-derived polypeptide on a surface thereof,

wherein the HPV E7 protein-derived polypeptide is fused with an anchor protein cA derived from AcmA to form a fusion protein, or is expressed from a sequence of a nucleic acid coding for the HPV E7 protein-derived polypeptide linked to an anchor gene prtP,

wherein the HPV E7 protein-derived polypeptide is included in an amount of 0.03 μg to 1.0 μg per 1×10^8 lactic acid bacteria on the surface of the bacterium.

2. The lactic acid bacterium-containing composition according to claim 1, wherein the HPV E7 protein-derived polypeptide is bound on the surface of the lactic acid bacteria.

3. The lactic acid bacterium-containing composition according to claim 1, wherein the HPV E7 protein-derived polypeptide is expressed on the surface of the lactic acid bacteria.

4. The lactic acid bacterium-containing composition according to any one of claims 1 to 3, wherein the lactic acid bacteria is Lactobacillus casei.

5. Use of the lactic acid bacterium-containing composition according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of at least one of an HPV infectious disease and an HPV-associated tumor, wherein the medicament is to be administered via oral administration.

6. Use of the lactic acid bacterium-containing composition according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of at least one of a cervical intraepithelial neoplasia and an early-stage cervical cancer.

7. Use of the lactic acid bacterium-containing composition according to any one of claims 1 to 4 in the manufacture of a medicament, wherein the medicament is to be used as a mucosal immunity-inducing agent.

8. The lactic acid bacterium-containing composition according to any one of claims 1 to 4 for use in the treatment of at least one of an HPV infectious disease and an HPV-associated tumor, wherein the medicament is to be administered via oral administration.

9. The lactic acid bacterium-containing composition according to any one of claims 1 to 4 for use in the treatment of at least one of a cervical intraepithelial neoplasia and an early-stage cervical cancer.

10. The lactic acid bacterium-containing composition according to any one of claims 1 to 4 for use as a mucosal immunity-inducing agent.